Royce & Associates LP bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 12,938 shares of the specialty pharmaceutical company's stock, valued at approximately $468,000.
A number of other institutional investors and hedge funds have also made changes to their positions in SUPN. Swiss National Bank lifted its stake in shares of Supernus Pharmaceuticals by 0.7% during the 4th quarter. Swiss National Bank now owns 108,400 shares of the specialty pharmaceutical company's stock worth $3,920,000 after purchasing an additional 800 shares during the last quarter. Great Lakes Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $6,131,000. HighTower Advisors LLC boosted its holdings in shares of Supernus Pharmaceuticals by 7.3% in the 4th quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock valued at $330,000 after buying an additional 624 shares in the last quarter. Argentarii LLC purchased a new position in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $271,000. Finally, Raymond James Financial Inc. purchased a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $6,847,000.
Supernus Pharmaceuticals Price Performance
NASDAQ:SUPN traded down $0.72 during trading hours on Wednesday, hitting $32.33. 277,635 shares of the company were exchanged, compared to its average volume of 467,034. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of 30.22 and a beta of 0.83. The company's 50 day moving average price is $35.49 and its 200-day moving average price is $35.05.
Insider Transactions at Supernus Pharmaceuticals
In other news, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,104 shares of company stock worth $440,263. Company insiders own 9.30% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com lowered Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday.
Read Our Latest Analysis on Supernus Pharmaceuticals
Supernus Pharmaceuticals Company Profile
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Read More
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
